CONCLUSIONS AND IMPLICATIONS
CAG can ameliorate the T2DM-related metabolic syndromes of ZDF
rats by acting on the SGLT2, which provides a certain references for the
application of CAG in T2DM therapy.
Keywords: type 2 diabetes mellitus, Cycloastragenol,
Astragaloside IV, hyperglycemia, cardiovascular disease, SGLT2.